51552-16-0

Basic information

• Product Name: (Dimethylamino)acetyl chloride
• Synonyms: (Dimethylamino)acetyl chloride
• CAS NO: 51552-16-0
• Molecular Formula: C₄H₈ClNO
• Molecular Weight: 121.57
• Mol File: 51552-16-0.mol
• Article Data: 10

Chemical Properties

• Melting Point: 110-113℃
• Boiling Point: 114.8 °C at 760 mmHg
• Flash Point: 23.2 °C
• Appearance: /
• Density: 1.101 g/cm³
• PKA: 6.79±0.28(Predicted)
• CAS DataBase Reference: (Dimethylamino)acetyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: (Dimethylamino)acetyl chloride(51552-16-0)
• EPA Substance Registry System: (Dimethylamino)acetyl chloride(51552-16-0)

Safety Data

• Hazardous Substances Data: 51552-16-0(Hazardous Substances Data)

Usage

Description

(Dimethylamino)acetyl chloride, also known as N,N-Dimethylaminoacetyl Chloride, is an organic compound with the chemical formula C4H8ClNO. It is a derivative of acetyl chloride, featuring a dimethylamino group attached to the acetyl moiety. (Dimethylamino)acetyl chloride is known for its reactivity and is commonly utilized in the synthesis of various pharmaceutical compounds and organic molecules.

Uses

Used in Pharmaceutical Industry:
(Dimethylamino)acetyl chloride is used as a reagent for the synthesis of novel amino-pyrimidine inhibitors. These inhibitors play a crucial role in targeting insulin-like growth factor 1 (IGF-1) and insulin receptors kinase. The application of this compound in the pharmaceutical industry is significant due to its ability to enhance cell potency and improve hERG inhibition, which are essential factors in the development of effective drugs for various diseases.
In the field of drug discovery, (Dimethylamino)acetyl chloride is employed as a key intermediate in the synthesis of potential therapeutic agents. Its unique reactivity allows for the creation of new chemical entities with improved pharmacological properties, such as increased potency, selectivity, and reduced side effects. This makes it a valuable tool in the ongoing efforts to develop innovative treatments for a wide range of medical conditions.
Furthermore, (Dimethylamino)acetyl chloride can also be used in the development of drug delivery systems, where its reactivity can be harnessed to create novel carriers for targeted drug delivery. This application can potentially improve the bioavailability and therapeutic outcomes of various drugs, making it an important component in the advancement of pharmaceutical technology.

Upstream product

• 2491-06-7 N,N-dimethylglycine hydrochoride 
• 1118-68-9 dimethylaminoacetic acid 

Downstream Products

• 1229217-96-2 C₁₉H₂₁N₃O₇ 
• 1262446-30-9 5-dimethylamino-2-methylsulfanyl-3-p-tolylpyrimidin-4(3H)-one 
• 31208-89-6 Dimethylamino-thioessigsaeure- 
• 73823-86-6 N,N-diethyl-glycine 4,5-dihydro-thiazol-2-ylamide 
• 1188424-65-8 10-(2-(dimethylamino)acetamido)-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydro-7,10-ethanopyrimido[1,2-a]azepine-2-carboxamide 
• 1361951-26-9 2-(dimethylamino)-1-(4-(((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)methyl)piperidin-1-yl)ethanone 
• 1604821-42-2 C₂₄H₂₆N₄O₄S 
• 1035976-22-7 (4S,4aS,5aR,12aS)-4-dimethylamino-7-[3-(2-dimethylamino-acetylamino)-phenyl]-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide 

Relevant articles and documents

Testosterone 17β-N,N-dimethylglycinate hydrochloride: A prodrug with a potential for nasal delivery of testosterone

The purpose of this study was to examine the potential of the nasal route for the systemic delivery of the poorly water-soluble drug testosterone (TS) using a water-soluble prodrug, TS 17β-N,N-dimethylglycinate hydrochloride. The physicochemical properties of the prodrug, in vitro hydrolysis in human liver homogenate, and in vivo nasal and intravenous experiments were performed in rats. The aqueous solubility of the prodrug was more than 100 mg/mL, compared with 0.01 mg/mL for TS, and its log partition coefficient between 0.05 M, phosphate buffer (pH 6) and octanol was 2.4. The prodrug was found to generate TS in 33% human liver homogenate and was absorbed from the nasal cavity rapidly and quantitatively. The bioavailabilities of both the prodrug and TS after nasal administration of the prodrug were similar to that after equivalent intravenous doses. These studies in rats suggest that this water-soluble prodrug of TS may have therapeutic utility for the management of TS deficiency.

NOVEL ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF

Disclosed are a novel isoindoline derivative, a pharmaceutical composition and use thereof. The compound of formula I, or the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotopic compound, metabolite or prodrug thereof disclosed in the invention can regulate the generation and/or activity of PDE4 and/or TNF-α so as to effectively treat cancer and inflammatory diseases.

IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Synthesis, cleavage, and antifungal activity of a number of novel, water-soluble ester prodrugs of antifungal triazole CS-758

In this study, the synthesis and evaluation of a number of esters of CS-758 as injectable prodrugs are described. Phosphoryl ester 1a was soluble in water (>30 mg/mL) and was converted to CS-758 in human liver microsome. It was also converted to CS-758 in rats after iv administration, wherein the bioavailability of CS-758 was 53%. Compound 1a (iv) reduced the viable cell counts in kidneys in a murine systemic Candida albicans infection model, wherein the effect was comparable to or slightly superior to that of CS-758 (po). The prodrug 1a proved to be a promising injectable antifungal agent whose further evaluation is warranted.